Is In-Clinic Ketamine Therapy Safer Than At-Home Treatment?

Is In-Clinic Ketamine Safer Than At-Home Treatment?

Not according to the published evidence. Each of the specific risks cited as a reason ketamine belongs in a clinic has been studied, and the findings point to route, dose, and protocol design rather than to the setting itself.

• Breathing. Ketamine's respiratory safety record comes largely from emergency medicine, where it is given at two to four times psychiatric doses. Across 12,780 such sedations there were no deaths and no intubations, and no respiratory adverse events were reported across 11,441 at-home patients.^2,14
• Blood pressure. The rise is real, and it is largest with intravenous delivery because the full dose enters circulation at once. Routes used at home absorb through tissue and peak lower, and what the response calls for is a cuff and a threshold rather than a building.^5,6
• Dissociation. It peaks at around 40 minutes, resolves within two hours, and becomes milder across a course rather than more intense. Structured at-home protocols require another person to be present throughout the session.^5,9,10
• Dependence. Across 1,495 patients on maintenance ketamine, the published literature records one case of addiction. At-home prescribing addresses the risk through supply limits, with three doses shipped at a time and no refills.¹²
• Bladder health. Cystitis is documented in frequent high-dose recreational use and has not been reported at prescribing-guideline doses in therapy. The variable is cumulative exposure, not location.¹¹

Each of those is examined in full below, alongside the FDA's warning on compounded ketamine and the question of whether an evidence gap still exists. For the wider set of eligibility and safety questions, our safety and eligibility hub covers screening, contraindications, and medication interactions in detail.

What the Research Shows About Ketamine and Breathing

Depressed breathing is one of the most cited risks of ketamine treatment and a central reason clinics are presented as safer. Ketamine at psychiatric doses has an exceptionally well-documented respiratory safety record, and the risk has not materialized in the settings best equipped to detect it, at doses several times higher than any at-home protocol uses.

Why Breathing Comes Up as a Concern

Ketamine is an anesthetic. At full anesthetic doses, respiratory depression is a genuine clinical consideration, and anesthesia is delivered with airway management immediately available. That concern carries into psychiatric use on the assumption that the same risk applies, and that someone trained to manage an airway therefore needs to be in the room.

What the Data Shows About Ketamine and Respiratory Safety

The risk profile of anesthetic ketamine does not carry over to psychiatric dosing, because the exposures are not comparable. A standard 0.5 mg/kg therapeutic dose produces peak plasma concentrations of 70 to 200 ng/mL, against 2,000 to 3,000 ng/mL for surgical anesthesia.⁴

Emergency departments sit between the two, using ketamine at 1.0 to 2.0 mg/kg intravenously for procedural sedation, roughly two to four times a psychiatric dose. Our guide to ketamine types and dosages covers how therapeutic dosing is set.¹³ Across 12,780 such sedations recorded in a multicenter registry spanning 84 institutions over 20 years, critical adverse events occurred in 2 patients, or 0.016%. There were no deaths, no cardiac arrests, no intubations, and no chest compressions.¹⁴ A separate systematic review of 20 studies covering 67,871 children reported no deaths and no permanent adverse outcomes, with serious adverse events in 0.34%.²²

The emergency medicine practice guideline is direct about what that record supports: "the literature strongly supports the safety of ketamine in patients breathing room air," and supplemental oxygen "is not mandatory."¹³ The same guideline notes that despite 40 years of continual worldwide use, there are no documented reports of clinically significant ketamine-associated aspiration outside of ill neonates.¹³

The peer-reviewed research on at-home treatment is consistent with that record. Across 11,441 patients on the Mindbloom protocol, the largest published dataset of its kind, no respiratory adverse events were reported.²

What Happens to Blood Pressure During a Ketamine Session

Blood pressure does rise during ketamine treatment, and it is the most substantive safety argument for in-clinic care. The size of that rise tracks how fast the dose reaches the bloodstream, which makes it largest with intravenous delivery and answerable at home with a monitor and a threshold rather than a building.

Why Blood Pressure Comes Up as a Concern

Ketamine briefly stimulates the cardiovascular system, and elevated readings during treatment are common and well documented. Infusion clinics measure vital signs throughout a session for this reason, and the FDA names increased blood pressure among the risks of compounded ketamine used without monitoring.²¹

What the Data Shows About Ketamine and Blood Pressure

The cardiovascular response is driven by peak concentration, which means it is largest with the fastest route. Intravenous delivery puts the full dose into circulation with no absorption step and peaks within minutes. Sublingual tablets are roughly 30% bioavailable and subcutaneous injection is 90% to 95%, but both absorb through tissue first, producing a flatter and later peak.⁵ The shared variable is the shape of the concentration curve rather than bioavailability, and our companion articles on whether IV ketamine acting faster makes it more effective and whether higher bioavailability means better results cover the pharmacokinetics in full.

The intravenous figures show the upper bound. In the largest published in-clinic safety analysis, covering 203 patients and 723 infusions, blood pressure rose an average of 17.9 points systolic and 12.9 diastolic. Across that study, 44.3% of patients crossed the clinic's threshold of 165/100 at least once and 5.4% required medication, but 89% returned to baseline within 20 minutes.⁶ No hypertensive emergency has been reported anywhere in the therapeutic ketamine literature.

The monitoring standard rests on less than most people assume. The American Psychiatric Association task force wrote in 2017 that "there are relatively low levels of evidence to support the use of any specific monitoring methods in reducing the risks of ketamine treatment with doses that are lower than those used in anesthesia."⁴ The emergency medicine guideline goes further, stating that "blood pressure measurements after the initial value are generally unnecessary."¹³

What blood pressure monitoring requires is a cuff and a threshold, both of which travel. Mindbloom ships a monitor with every treatment kit and gates each session on it, with no session proceeding above 150/100 or a heart rate above 100 beats per minute, a stricter threshold than the 165/100 used to define a treatment-emergent event in the clinic study above. The peer-reviewed analysis of the subcutaneous protocol states it directly: "remote guardrails, such as remote clinician check-ins, video-verified self-injection competency, and the provision of BP monitoring equipment at home, can effectively decentralize ketamine care without compromising patient safety."³

What the Research Shows About Dissociation Outside a Clinical Setting

Dissociation is frequently cited as a reason ketamine requires supervision. It is time-limited, dose-dependent, and becomes milder over a course of treatment, and what it calls for is a prepared person in the room rather than a particular kind of room. Our guide to what ketamine feels like describes the experience in more detail.

Why Dissociation Comes Up as a Concern

Dissociation can be intense, particularly for someone who has not experienced it before. The argument is that if it becomes overwhelming, a clinic with trained staff on hand is better equipped to manage it than a home is.

What the Data Shows About Dissociation

Dissociation follows a predictable arc and lessens with repetition, and structured at-home protocols require another person to be present for precisely the reason the concern identifies.

It peaks around 40 minutes and resolves within one to two hours in every study that measured it with a validated instrument.⁵ It also attenuates across a course. Phillips et al. 2019 recorded a drop in dissociation scores from 18.0 after a first infusion to 4.6 by the final one, and Singh et al. 2016 found the same pattern, from 9.6 on day one to 4.3 by day 15.^9,10

Overwhelming experiences are uncommon. Among 11,441 patients on the Mindbloom protocol, 12, or 0.1%, discontinued because of intense dissociation or another psychologically overwhelming experience.² In that protocol a peer treatment monitor is physically present for every session, confirmed on camera before the first one, with the on-call clinician's direct number.

Whether a clinic is the calmer environment is also worth asking. When a UK research group asked patients to rate the clinical setting where they received ketamine, several described it as unsuitable, citing noise, movement around them, and hearing other distressed patients nearby.¹⁵ Set and setting are the two variables the psychedelic literature treats as most predictive of a difficult experience.

What the Research Shows About Ketamine Misuse and Dependence

Ketamine's abuse potential is a real feature of its regulatory profile, and at-home treatment means the medicine is in a patient's possession between sessions. Dependence in supervised sub-anesthetic protocols is rare in the published record, and it is managed at home through prescribing limits rather than observation.

Why Misuse Comes Up as a Concern

Ketamine is a Schedule III controlled substance, and at-home treatment means the medication is in a patient's possession between sessions.

What the Data Shows About Misuse and Dependence

Dependence tracks dose and frequency rather than supervision, and in therapeutic protocols it appears rarely enough to be counted in single cases.

A systematic review of maintenance ketamine treatment covering 1,495 patients across 45 studies identified one case of addiction and one case of persistent cognitive disturbance in the entire body of literature.¹² In a separate series of 6,630 patients receiving repeated parenteral ketamine, adverse events that prompted discontinuation "did not include addiction or cognitive deficits."¹²

The at-home data is consistent with that. Among 11,441 patients on the Mindbloom protocol, drug cravings were reported by 0.2% to 0.4%.²

Structured protocols manage the possession question through prescribing limits rather than observation. In the Mindbloom protocol, prescriptions ship three doses at a time with no refills, capped at six, and clinicians check a state prescription drug monitoring database before every order.

What the Research Shows About Ketamine and Bladder Health

Bladder damage is a documented consequence of frequent high-dose recreational ketamine use. It has not been reported at prescribing-guideline doses in therapeutic settings, because the risk scales with cumulative exposure rather than with where the medicine is taken.

Why Bladder Health Comes Up as a Concern

Ketamine-induced cystitis is well described in the recreational literature, including cases severe enough to require surgery, and the FDA names lower urinary tract symptoms among the risks of compounded ketamine.²¹

What the Data Shows About Ketamine and the Bladder

Bladder injury is a function of cumulative exposure, and therapeutic protocols operate at a small fraction of the dose and frequency at which it appears.

Among 90 recreational users surveyed in the United Kingdom, 30% reported at least one bladder symptom.¹¹ In therapeutic use, lower urinary tract symptoms were reported by 1.75% of esketamine patients compared with 0.30% on placebo, and approximately 0.6% developed cystitis over a year of treatment.¹¹ The review that assembled those figures concluded that "severe interstitial or ulcerative cystitis requiring surgical intervention (as has been reported in the substance abuse literature) has not been reported among patients receiving doses of esketamine/ketamine in line with prescribing guidelines for depression."¹¹

Among 11,441 patients on the Mindbloom protocol, dysuria was reported by 0.2% to 0.5%.²

The mechanism is dose-dependent, and bladder pathology is attributed specifically to daily or near-daily use.¹¹ That places the exposure question with high-frequency protocols rather than with defined treatment courses, a distinction worth applying when comparing at-home programs to each other.

What the FDA Warning on Compounded Ketamine Says

The FDA warned in October 2023 about compounded ketamine products used at home without provider monitoring. The warning addresses compounded products as a category, identifying risks and calling for monitoring, which is a statement about how ketamine should be prescribed rather than about where it should be taken.

Why the FDA Warning Comes Up

It is the most frequently cited document in arguments against at-home ketamine, and it is often presented as a federal determination that at-home treatment is unsafe.

What the Warning Actually Says

The warning identifies categories of risk and calls for monitoring. It does not evaluate any particular program, and it does not distinguish between protocols that screen, monitor, and limit prescribing and those that do not.

It names abuse and misuse, psychiatric events, increased blood pressure, slowed breathing, and lower urinary tract symptoms, noting that use without health care provider monitoring for sedation, dissociation, and vital sign changes may put patients at risk.²¹ Each of those specific risks is addressed in the sections above.

Two pieces of context matter. Ketamine's use for depression, anxiety, and PTSD is off-label in every setting including IV clinics, a standard practice accounting for roughly 21% of all prescriptions written in the United States.¹⁸ And compounded medications are prepared by licensed pharmacies subject to state board, DEA, and FDA inspection, which our guide to whether compounded medications are FDA approved covers in detail.

Is There an Evidence Gap for At-Home Ketamine Safety?

The absence of at-home safety data was a legitimate concern when the field raised it in 2017. It has since been addressed by three peer-reviewed studies covering more than 15,000 patients, while the setting that gap was measured against has never produced an equivalent dataset. Our clinical research page collects the published work.

Why the Evidence Gap Comes Up

In 2017 the American Psychiatric Association task force wrote that it "strongly advise[d] against the prescription of at-home self-administration of ketamine," adding that "it remains prudent to have all doses administered with medical supervision until more safety information obtained under controlled situations can be collected."⁴ In 2021 the 25-author expert consensus in the American Journal of Psychiatry listed characterization of "less restrictive treatment environments (e.g., in physicians' offices or self-administration at home under certain conditions)" among the field's research priorities.⁵ Both described a gap in the evidence rather than a finding of harm.

What the Data Now Shows

The information the field asked for exists. Three peer-reviewed studies of at-home treatment on the Mindbloom protocol have been published since 2022:

• Hull et al. 2022 followed 1,247 patients on the sublingual protocol, reporting side effects in 4.7% after session two and 3.8% after session four, with four patients (0.3%) discontinuing because of side effects.¹
• Mathai et al. 2024 analyzed 11,441 patients on the same protocol and found serious adverse events in 6 patients (0.05%), all psychiatric in nature, with discontinuation due to side effects in 46 patients (0.4%).²
• Parks et al. 2026 analyzed 3,041 patients on the subcutaneous protocol over 22 months and reported three serious adverse events (0.08%): one psychotic episode following a first treatment, judged likely related to treatment, and two deaths by suicide where attributability could not be determined.³

These are real-world observational studies rather than randomized trials, which means no placebo comparison and patient-reported rather than actively solicited side effects. They are also the study design that produces most post-approval safety data for FDA-approved medications, and their findings apply to the protocol studied rather than to at-home ketamine as a category.

For context on the comparison, the in-clinic record is less complete than the assumption suggests. The APA task force noted that "despite more than 45 years of clinical experience with ketamine as an anesthetic agent, there are no postmarketing surveillance data on the use of ketamine for any psychiatric indication."⁴ The expert consensus states that adverse events with intravenous ketamine are "not systematically reported and are likely subject to reporting bias."⁵ And the largest meta-analysis in the field, covering 49 trials and 3,299 participants, synthesized a single safety measure, which its own authors called "a coarse measure of safety."⁸

Which At-Home Providers Have Published Safety Data?

One. Mindbloom is the only at-home ketamine provider that has published peer-reviewed safety data on its own protocol, across three studies covering both sublingual and subcutaneous administration.^1,2,3 Peer-reviewed publication means findings submitted to a journal, reviewed by independent researchers, and accepted, which is the standard by which a clinical claim becomes verifiable rather than asserted.

That is a scoping point, and it cuts in a specific direction. Published evidence supports conclusions about a specific studied protocol, meaning those exclusion criteria, that dose range, that monitoring model. It does not validate at-home ketamine as a category, because no other provider has published protocol-specific safety data. The accurate word for every other at-home protocol is unstudied, not unsafe.

That distinction matters most for daily low-dose protocols, which have never been tested prospectively in a general population. The two closest published studies are a 28-day trial of once-daily oral ketamine in 14 hospice patients, and a 21-day trial of three-times-daily oral esketamine in 7 patients.^16,17 Neither examined a general at-home population. Since bladder risk is attributed to daily or near-daily use in a dose-dependent way, frequency is precisely the variable that would need studying, and our guide to whether daily low-dose ketamine is effective covers that evidence in more depth.

When comparing at-home providers, the useful question is not whether at-home ketamine is safe in general. It is whether that specific protocol has been studied and published, and where you can read it.